ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

ULT Ultrasis

0.095
0.00 (0.00%)
31 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Ultrasis LSE:ULT London Ordinary Share GB0001494979 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.095 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Ultrasis PLC Board Changes and Financing Update (5914T)

07/10/2014 7:00am

UK Regulatory


Ultrasis (LSE:ULT)
Historical Stock Chart


From Jun 2019 to Jun 2024

Click Here for more Ultrasis Charts.

TIDMULT

RNS Number : 5914T

Ultrasis PLC

07 October 2014

Ultrasis plc

("Ultrasis" or the "Company")

Board Changes and Financing Update

The Company announces that Gerald Malone and Michael Mills, who have been non-executive directors for 14 and 11 years respectively, have resigned with immediate effect. The Board thanks them for their years of service and valuable input.

John Smith, CEO, will become interim Executive Chairman following Gerald Malone's departure and the Company will now seek an alternative Chairman and non-executive director to provide an appropriate board structure.

As initially announced on 29 January 2013, the Company has loan facilities in place with Paul Bell, a substantial shareholder in the Company, of which approximately GBP700,000 was undrawn at the end of September 2014. Under the terms of the loan facilities, the Company is entitled to draw down funds to a maximum amount of GBP1 million in any rolling 12 month period, a limit the Company has already reached, However, Mr. Bell has recently written to the Company stating that he is prepared to continue to consider on-going requests for draw-downs under the loan facilities which are in excess of the rolling limit, subject to, inter alia, a review of the Company's short and medium term working capital requirements and the Board seeking cancellation of the Company's shares to trading on AIM.

Consequently, the Board intends shortly to send a circular to shareholders seeking the cancellation of the Company's shares to trading on AIM. Further announcements will be made in due course.

For all enquiries relating to Ultrasis please contact:

 
Ultrasis plc                     Tel: +44 (0) 20 7535 2050 
John Smith, Interim Executive 
 Chairman 
 
finnCap Ltd                      Tel: +44 (0) 20 7220 0500 
Geoff Nash / Charlotte Stranner 
 
 

Notes to Editors:

Ultrasis is a healthcare company with core expertise in health, psychology, software development and programme management. We deliver a range of healthcare products to the consumer, the NHS, the corporate sector and other healthcare providers in the UK and Internationally. Ultrasis was the first company to offer computerised products based on Cognitive Behavioural Therapy (CBT) and interactive multimedia, and is still the world leader in this field.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCDGBDGXUGBGSL

1 Year Ultrasis Chart

1 Year Ultrasis Chart

1 Month Ultrasis Chart

1 Month Ultrasis Chart